Volume 5 Supplement 4

Abstracts from the 10th Symposium of Experimental Rhinology and Immunology of the Nose (SERIN 2015)

Open Access

The ‘GA²LEN Sinusitis Cohort’: an introduction

  • Griet Vandeplas1,
  • Asif Khan2,
  • Thi Minh Thao Huynh3,
  • Peter Tomassen1,
  • Thibaut van Zele1,
  • Lars-Olaf Cardell4,
  • Julia Arebro4,
  • Heidi Olze5,
  • Ulrike Foerster5,
  • Marek Leszek Kowalski6,
  • Agnieszka Olszewska-Ziąber6,
  • Wytske Fokkens7,
  • Cornelis van Drunen7,
  • Joaquim Mullol8,
  • Peter Hellings9,
  • Valérie Hox9,
  • Elina Toskala10,
  • Glenis Scadding11,
  • Valerie Lund12 and
  • Claus Bachert1
Clinical and Translational Allergy20155(Suppl 4):O1

https://doi.org/10.1186/2045-7022-5-S4-O1

Published: 26 June 2015

Background

The Global Allergy and Asthma European Network (GA2LEN) is a network of the leading European allergy clinical and research facilities and the GA2LEN Sinusitis Cohort is a database within this network. The aim of this cohort is to intensify research on rhinosinusitis pheno- and endotypes, thus differentiating chronic rhinosinusitis (CRS) into smaller disease entities based on clinical, biological, and patient-reported outcomes.

Methods

Patients (N = 869) from 9 participating outpatient ENT clinics recruited to participate in this cross-sectional, multicentre cohort study were assigned to 3 groups: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), both diagnosed using EPOS 2012 guidelines; and control defined as an unmatched cohort of patients undergoing nasal turbinate surgery with or without allergy symptoms. Patient subgroups were compared by clinician reported, patient reported, imaging, endoscopy, lung function, and biomarker outcomes.

Results

Overall, 51.2%, 27.3%, and 21.5% of patients were in the CRSwNP, CRSsNP, and control groups, respectively. Across groups, mean age was 42.1 years (range 15–76 years), 55.0% were male, and 95.5% were Caucasian. Comorbid allergic rhinitis was diagnosed in 33.2%, 29.0%, and 23.8% of patients in the CRSwNP, CRSsNP, and control groups, respectively. Of all patients, 33.2% had comorbid asthma, which was significantly (p < 0.0001) more frequent in the CRSwNP (49.6%) than CRSsNP (20.2%) group. CRSwNP patients reported late age of onset for asthma, whereas CRSsNP patients reported early age of onset. Among CRSwNP and CRSsNP patients who did not report asthma, 59.8% and 41.9%, respectively, had an FEV1/FVC ratio of ≤ 80% (p = 0.063). Contact allergy was present significantly more often in CRSsNP than CRSwNP patients (15.1% vs 5.2%; p = 0.0001). Overall, 4.4% of all patients reported aspirin intolerance, which was significantly more frequent in CRSwNP vs CRSsNP patients (7.4% vs 1.3%; p < 0.0001); among these CRSwNP patients, 90.9% had asthma, forming the Aspirin Exacerbated Respiratory Disease (AERD) subgroup. A significantly higher number of CRSwNP patients reported previous surgery vs CRSsNP patients (45.9% vs 22.7%; p < 0.0001).

Discussion

The GA2LEN Sinusitis cohort was not intended to be population representative; however, it is a large cohort of patients recruited throughout Europe with clinical, biomarker, as well as patient-reported outcomes.

Authors’ Affiliations

(1)
Ghent University, Upper Airways Research Laboratory
(2)
Sanofi, Health Economics and Outcomes Research
(3)
AIXIAL, Biometry Department, Levallois-Perret
(4)
Karolinska Institutet, Division of ENT Diseases, CLINTEC
(5)
Dept of Otorhinolaryngology, Charité-Universitätsmedizin Berlin
(6)
Medical University of Lodz, Dept of Immunology, Rheumatology and Allergy
(7)
Academic Medical Centre, Dept of Otorhinolaryngology
(8)
IDIBAPS, Clinical & Experimental Respiratory Immunoallergy
(9)
Dept of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven
(10)
Dept of Otolaryngology-Head and Neck Surgery, Temple University School of Medicine
(11)
Royal National Throat, Nose and Ear Hospital, Allergy and Medical Rhinology Unit
(12)
Royal National Throat, Nose and Ear Hospital, Rhinology Unit

Copyright

© Vandeplas et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement